We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Axovant Gene Therapies Ltd | NASDAQ:AXGT | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 2.10 | 2.09 | 2.11 | 0 | 01:00:00 |
Commission File Number: 001-37418 |
Sio Gene Therapies Inc. | ||
(Exact name of registrant as specified in its charter) | ||
1501 Broadway, 12th Floor New York, NY 10036 (646) 677-6770 | ||
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices) | ||
Common Stock, $0.00001 par value | ||
(Title of each class of securities covered by this Form) | ||
None | ||
(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains) |
Rule 12g-4(a)(1) | ☒ | |||||||
Rule 12g-4(a)(2) | ☐ | |||||||
Rule 12h-3(b)(1)(i) | ☒ | |||||||
Rule 12h-3(b)(1)(ii) | ☐ | |||||||
Rule 15d-6 | ☐ | |||||||
Rule 15d-22(b) | ☐ |
SIO GENE THERAPIES INC. | |||||||||||||||||
Dated: | April 25, 2023 | ||||||||||||||||
By: | /s/ David Nassif | ||||||||||||||||
Name: | David Nassif | ||||||||||||||||
Title: | Chief Executive Officer; Chief Financial Officer; Chief Accounting Officer; and General Counsel |
1 Year Axovant Gene Therapies Chart |
1 Month Axovant Gene Therapies Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions